Trial Profile

A Phase 1, Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability and Efficacy of BST02 in Treating Locally Advanced Liver Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 23 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BST-02 (Primary)
Indications Cholangiocarcinoma; Liver cancer
Focus Adverse reactions
Sponsors BioSyngen

Most Recent Events

19 Sep 2024 According to BioSyngen media release, the first patients have been enrolled in this trial and completion of this Phase I trial anticipated later this year.
01 Aug 2024 Status changed from planning to recruiting.
05 Feb 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com